Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Enapotamab vedotin |
Synonyms | |
Therapy Description |
Enapotamab vedotin (HuMax-Axl-ADC) is an antibody-drug conjugate comprising an AXL targeted antibody linked to the anti-microtubule compound MMAE, which potentially decreases tumor growth (J Clin Oncol 35, 2017 (suppl; abstr TPS2605), PMID: 32148495, PMID: 31600169). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Enapotamab vedotin | AXL-107-MMAE|HuMax-Axl-ADC | AXL Antibody 5 | Enapotamab vedotin (HuMax-Axl-ADC) is an antibody-drug conjugate comprising an AXL targeted antibody linked to the anti-microtubule compound MMAE, which potentially decreases tumor growth (J Clin Oncol 35, 2017 (suppl; abstr TPS2605), PMID: 32148495, PMID: 31600169). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02988817 | Phase Ib/II | Enapotamab vedotin | HuMax-AXL-ADC Safety Study in Patients With Solid Tumors | Completed | USA | ESP | BEL | 3 |